isotretinoin and Pneumonia

isotretinoin has been researched along with Pneumonia* in 2 studies

Trials

1 trial(s) available for isotretinoin and Pneumonia

ArticleYear
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
    Haematologica, 2007, Volume: 92, Issue:8

    Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to toxicity. According to international working group criteria, three patients (16%) responded to treatment. No correlation between VPA serum level, histone acetylation or clinical response was observed.

    Topics: Acetylation; Aged; Aged, 80 and over; Calcitriol; Cheilitis; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Fatigue; Histones; Humans; Isotretinoin; Middle Aged; Myelodysplastic Syndromes; Pneumonia; Protein Processing, Post-Translational; Treatment Outcome; Valproic Acid

2007

Other Studies

1 other study(ies) available for isotretinoin and Pneumonia

ArticleYear
Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect.
    The British journal of dermatology, 1994, Volume: 131, Issue:5

    The effects of systemic glucocorticoid and isotretinoin treatments on type I and type III collagen synthesis in intact skin were investigated by measuring the carboxyterminal and aminoterminal propeptides of type I procollagen, and the aminoterminal propeptide of type III procollagen, in suction blister fluid (SBF), in a study of 27 patients. All three parameters were significantly lower in the SBF of glucocorticoid-treated patients than in controls or patients undergoing treatment with isotretinoin, whereas the latter two groups did not differ significantly from each other. During glucocorticoid treatment, the concentrations of the procollagen propeptides were only about 20% of the corresponding control values, indicating that systemic therapy with prednisone at a dose of 0.48 mg/kg per day almost totally abolishes collagen synthesis in the skin. These results indicate that systemic glucocorticoid treatment suppresses the synthesis of both type I and type III collagen in the dermis, and suggest that many side-effects of these drugs, such as atrophy of the skin, are due to this inhibition. Systemic isotretinoin treatment did not stimulate skin collagen synthesis. Thus, its regenerative effect on connective tissue may be mediated by mechanisms other than direct stimulation of collagen synthesis.

    Topics: Adult; Asthma; Blister; Collagen; Glucocorticoids; Humans; Isotretinoin; Peptide Fragments; Pneumonia; Prednisolone; Procollagen; Skin

1994